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Abstract
Background: In late spring 2009, concern was raised in Canada that prior vaccination with the 2008–09 trivalent inactivated
influenza vaccine (TIV) was associated with increased risk of pandemic influenza A (H1N1) (pH1N1) illness. Several
epidemiologic investigations were conducted through the summer to assess this putative association.
Methods and Findings: Studies included: (1) test-negative case-control design based on Canada’s sentinel vaccine
effectiveness monitoring system in British Columbia, Alberta, Ontario, and Quebec; (2) conventional case-control design
using population controls in Quebec; (3) test-negative case-control design in Ontario; and (4) prospective household
transmission (cohort) study in Quebec. Logistic regression was used to estimate odds ratios for TIV effect on community- or
hospital-based laboratory-confirmed seasonal or pH1N1 influenza cases compared to controls with restriction, stratification,
and adjustment for covariates including combinations of age, sex, comorbidity, timeliness of medical visit, prior physician
visits, and/or health care worker (HCW) status. For the prospective study risk ratios were computed. Based on the sentinel
study of 672 cases and 857 controls, 2008–09 TIV was associated with statistically significant protection against seasonal
influenza (odds ratio 0.44, 95% CI 0.33–0.59). In contrast, estimates from the sentinel and three other observational studies,
involving a total of 1,226 laboratory-confirmed pH1N1 cases and 1,505 controls, indicated that prior receipt of 2008–09 TIV
was associated with increased risk of medically attended pH1N1 illness during the spring–summer 2009, with estimated risk
or odds ratios ranging from 1.4 to 2.5. Risk of pH1N1 hospitalization was not further increased among vaccinated people
when comparing hospitalized to community cases.
Conclusions: Prior receipt of 2008–09 TIV was associated with increased risk of medically attended pH1N1 illness during the
spring–summer 2009 in Canada. The occurrence of bias (selection, information) or confounding cannot be ruled out. Further
experimental and epidemiological assessment is warranted. Possible biological mechanisms and immunoepidemiologic
implications are considered.
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On 17 April 2009 a novel swine-origin influenza A (H1N1) virus
was identified as the cause of two pediatric cases of febrile
respiratory illness in California [1,2]. Shortly thereafter, this virus
was also identified as the cause of an outbreak of severe respiratory
illness occurring among young people in Mexico in March and
April [3,4]. Subsequent spread throughout North America and
elsewhere resulted in the declaration, on 11 June, of a phase 6
pandemic of the novel influenza A (H1N1) (now called pandemic
influenza A (H1N1) [pH1N1]) by the World Health Organization
(WHO) [5]. Early surveillance and immunogenicity data and
global summary by the WHO emphasized increased risk among
young people ,50 years of age [2,6,7].
Influenza vaccine is recommended and provided free in Canada
to children 6–23 months of age, elderly people, people of all ages
with designated high-risk conditions, and their household contacts
and care providers [8]. In Ontario, all residents $6 months of age
can access the influenza vaccine annually free of charge via a
universal immunization program initiated in 2000. Residents of
other provinces who are not among the high-risk or their contacts
are also encouraged to receive influenza vaccine, and this may be
provided free by their employers or they must purchase it. In its
annual update, WHO recommended changes to all three
components of the influenza vaccine for the 2008–09 season [8].
GlaxoSmithKline (GSK Fluviral; domestically manufactured) and
Sanofi Pasteur (Vaxigrip; imported) supply approximately 75%
and 25%, respectively, of the split trivalent inactivated influenza
vaccine (TIV) distributed each year in Canada; Quebec generally
receives a higher proportion of GlaxoSmithKline product (,95%
for 2008–09 and 2007–08) while Ontario generally receives less
(,67% for 2008–09 and 2007–08). Live attenuated influenza
vaccine is not yet approved for use in Canada.
During the last week of April, a school pH1N1 outbreak was
reported in a rural community of northern British Columbia (BC)
[9]. During outbreak investigation, an unexpected signal of
association between prior vaccination with TIV and fever/cough
illness was noted. Because these unexpected results were based on
a nonspecific outcome defined by clinical syndrome, separate
follow-up studies were arranged to investigate this initial signal
using more stringent methodologies based on laboratory-con-
firmed outcomes. We report the results of four epidemiologic
studies conducted during the summer of 2009 in Canada to assess
the putative association between vaccination with seasonal 2008–
09 TIV and pH1N1 illness.
Methods
The design, sample size, and outcomes evaluated in each of the
four studies to assess the association between prior 2008–09 TIV
receipt and risk of pH1N1 illness are summarized in Table 1.
Ethics Statement
The studies described were approved by the relevant institu-
tional review boards of participating agencies/provinces as well as
nationally for the sentinel study, or were conducted as legally
mandated public health investigations for the Quebec and Ontario
case-control studies. Patients provided written informed consent
for the prospective cohort study and oral consent for the other
three studies.
National Sentinel Monitoring System
The four most populated provinces of Canada—BC, Alberta,
Ontario, and Quebec—conduct annual (November through April)
vaccine effectiveness (VE) monitoring through linked community-
based sentinel physician surveillance networks. Study methods,
implemented annually since 2004 and described in detail in prior
publications, are approved each year by ethics boards provincially
and nationally [10–12]. Designated sentinel sites in participating
provinces are provided kits with which clinicians submit
respiratory specimens (nasal or nasopharyngeal [NP]) for influenza
testing along with epidemiologic information collected in a
standardized way from eligible consenting patients presenting
within 7 days of onset of influenza-like illness (ILI). Following the
emergence of pH1N1 in mid-April, sentinel physicians in
participating provinces were instructed to continue their routine
VE monitoring activities, regardless of other testing guidelines to
clinicians.
Seasonal influenza analysis spanned ILI onset between 1
November 2008 and 31 March 2009. pH1N1 analysis spanned
ILI onset between 17 April and 22 July 2009. Testing for seasonal
influenza at designated provincial laboratories in BC, Ontario,
and Quebec consisted of real time reverse transcription PCR (RT-
PCR) screening for influenza A and B, followed by real time RT-
PCR subtyping (A/H1 or A/H3). In Alberta, all specimens were
tested by Luminex RVP Assay, which detects seasonal influenza,
pH1N1, and influenza B viruses and directly subtypes as A/H1 or
A/H3. Testing was modified in all provinces after 17 April to
detect pH1N1 using a conventional (end point) RT-PCR assay
(Text S1, Appendix A1). Sequence analysis was performed on a
subset of the PCR product in each province to validate specificity
of pH1N1 detection.
We used the test-negative case-control design: cases presented
with ILI and tested positive for seasonal or pH1N1 influenza,
depending upon the analysis period; controls presented with ILI
and tested negative for both seasonal and pH1N1 influenza.
Medically attended, laboratory-confirmed influenza is uncom-
mon, and thus case subjects are a small fraction of the total source
population. In addition, control subjects are a proportion of the
total population that reflects vaccine coverage and is anticipated
to be stable over both the seasonal and the pH1N1 analysis
periods. In that context, the odds ratio (OR) is appropriate to
estimate the risk ratio (RR) [13]. Logistic regression was thus used
to estimate ORs for a 2008–09 TIV effect on laboratory-
confirmed influenza through sequential models with adjustment
for age, chronic conditions, province, and timeliness of medical
visit (sex was also explored but was not influential in final models).
Per above, stratification at age 50 was decided a priori because of
age-related differences generally observed in the epidemiology of
pH1N1. VE is typically calculated as 1 – OR; here, we report
ORs directly [14]. Additional methodological detail, including
laboratory testing procedures, is provided in Text S1, Appendix
A1.
Quebec Population Case-Control Study
A legally mandated public health investigation was launched
in Quebec on 15 July 2009. Eligible cases included com-
munity (medically attended, nonhospitalized) and hospitalized
($24 hours) laboratory-confirmed detections of pH1N1 illness
with onset from 25 May to 1 July among residents of one of four
regions of Quebec together comprising 83% of community cases
and 78% of hospitalized cases in Quebec during that period. All
tests for pH1N1 were conducted at the provincial laboratory by
specific RT-PCR assay. The study sampling plan included all
hospitalized cases, approximately the same number of community
cases and a number of controls similar to the sum of the
hospitalized and community cases. The initial study plan was to
use a test-negative case-control approach. Results from this test-
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illness among prior TIV recipients, but more in-depth examina-
tion of participant profiles showed test-negative specimens to be
inadequate as controls for reasons outlined in Text S2, Appendix
B1a–B1e, notably because of early restrictions placed on testing in
Quebec. Quebec therefore moved to conventional sampling of
population controls from the community. Population controls
were selected by random-digit-dial to homes in numbers
proportionate to the number of cases per age group and region.
Trained interviewers conducted the survey from 17 July to 10
August 2009 using a standardized questionnaire. ORs were
derived through sequential logistic regression for a 2008–09 TIV
effect on pH1N1 cases compared to community controls with
adjustment for relevant covariates (Tables 1 and 5).
Ontario Test-Negative Case-Control Study
An urgent public health investigation was also conducted in
Ontario based on test-negative case-control design. A sample size
of 300 cases and 600 controls was estimated to be required a priori
based on TIV prevalence in controls of 30%–35%, an alpha
value of 0.05, and statistical power of 80% to detect an OR of at
least 1.5 for increased risk of medically attended pH1N1 illness.
Respiratory specimens (nasal, throat, or NP swabs) submitted for
influenza testing between 13 April and 20 July 2009 at the
provincial laboratory or the Mount Sinai Hospital/University
Health Network were identified as representing a community
(medically attended, non-hospitalized) or hospitalized case
(pH1N1-specific RT-PCR positive) or a control (RT-PCR
negative for all influenza). Hospitalized cases were identified
through linkage to the public health surveillance database. Test-
negative controls were medically attended community-based
patients. A sample of cases and controls was randomly selected
and frequency-matched by age group and week of specimen
collection. A standardized telephone survey of consenting cases
and controls was administered between 1 August and 4
September 2009 by trained interviewers from the Institute for
Social Research (ISR), York University, Toronto. In the analysis,
test date before versus after 11 June was incorporated as a binary
variable into all models since Ontario clinicians (outside the
sentinel system) were instructed after that date to submit
specimens only from high-risk patients and/or patients with
severe illness. ORs were derived through sequential logistic
regression for a 2008–09 TIV effect on pH1N1 cases compared
to test-negative community controls with adjustment for relevant
covariates (Tables 1 and 5).
Quebec Household Transmission Study
A prospective study to assess household pH1N1 transmission
and secondary attack rates (SARs) was conducted in Quebec City,
Canada from 27 May to 10 July 2009. The effect of TIV on
pH1N1 risk was thus also explored in this cohort. The household
primary case was the first laboratory-confirmed patient to present
with symptoms of respiratory illness in the household. Primary
cases were excluded as were symptomatic household members
without laboratory-confirmation of pH1N1 whose symptom onset
preceded that of the primary case. NP swabs were collected at
home from all household members as soon as possible after
identification of the primary case. Clinical information and self-
reported 2008–09 TIV status were collected using a standardized
questionnaire. NP swabs were tested by RT-PCR assay. SARs
were compared across vaccination groups by Chi-square (or Fisher
exact as appropriate) for children (,18 years) and adults ($18
years), and RRs were computed.
Results
National Sentinel Monitoring System
Inclusion/exclusion criteria and final participation in the seasonal
and pH1N1 sentinel study analysis periods are shown in Text S1,
Appendix A2. Influenza subtype and pH1N1 detection by province
are shown in Text S1, Appendix A3a/b, and the epidemic curve of
influenza test results by subtype and week of ILI onset is shown in
Text S1, Appendix A4. There were 1,529 specimens included in the
overall seasonal analysis, of which 672 (44%) were influenza positive;
by subtype these included 253 A/H3 (38%), 249 B (38%), and 160
A/H1 (24%). Ten were non-subtypeable. There were 711 specimens
included in pH1N1 analyses, of which 175 (25%) were influenza
positive, 144 (82%) for pH1N1 (20% pH1N1 positivity), 29 (17%) for
seasonal influenza, and two of unknown subtype. Seasonal influenza
viruses were detected in 28 sentinel specimens with ILI onset between
20 April and 10 May 2009, including 14 A/H3 (50%), 11 B (39%),
and three A/H1 (11%); A/H1 was detected in one specimen
thereafter.
The profile of participants is comparable between seasonal and
pH1N1 analysis periods (Table 2; more detail in Text S1,
Appendix A5a/b). Young adults aged 20–49 years contributed
most to the sentinel study during both seasonal and pH1N1
analysis periods. In participating provinces, 9% of the general
population 12–19 years, and 10% aged 20–49 years, are estimated
from publicly available data to have vaccine-eligible chronic
conditions [15]. These proportions are comparable to those found
among seasonal and pH1N1 test-negative controls in the sentinel
study. Compared to population estimates of ,20%–25% for 50-
to 64-year-olds and ,35%–40% for those $65 years, the report of
chronic conditions was substantially higher among older adult
controls for both seasonal (64/172 [37%] and 57/85 [67%],
respectively) and pH1N1 (34/109 [31%] and 27/48 [56%])
analysis periods (Text S1, AppendixA5a/A5b) [15]. The propor-
tion immunized in 2008–09 among test-negative controls was
comparable for seasonal and pH1N1 analysis periods both overall
(287/857 [33%] and 166/536 [31%], respectively) and among
controls ages 20–49 years (86/384 [22%] and 63/272 [23%],
respectively). Overall, immunization coverage estimates among
controls were similar to those derived from the 2007–08 Canadian
Community Health Survey (CCHS), particularly among young
adults (Text S3, Appendix C) [16].
As in previous seasons, we found that prior vaccination with TIV
significantly reduced the risk of medically attended seasonal influenza
in 2008–09, with ORs consistently and significantly ,1( F i g u r e1 ,
Table 3). Conversely, receipt of TIV was associated with significantly
increased risk of medically attended pH1N1 illness with fully adjusted
OR (95% CI) of 1.68 (1.03–2.74) overall and 2.23 (1.31–3.79) for
participants ,50 years (Figure 1, Table 3). Fully adjusted sensitivity
analyses, further restricted to participants 20–49 years of age, to those
with ILI onset after mid-May (the period of greatest indigenous
pH1N1 circulation), or to the provinces of Quebec and Ontario
(more intense pH1N1 activity) gave consistent results (Table 3). ORs
were highest for a vaccineeffect onpH1N1 risk in Quebec. Caution is
required in the interpretation of a TIV effect for the age stratum .50
years owing to small sample size, wide confidence intervals spanning
1, and further anticipated variation of effect with advancing age and
immune status among older individuals [17,18]. Estimates for crude
and fully adjusted ORs for 2008–09 TIV effect on seasonal influenza
for the period 17 April to 30 May 2009 remained ,1, although
sample size was again small and statistical significance was not
achieved. In overall analyses, the crude and fully adjusted ORs for
2008–09 TIV in preventing seasonal influenza during the pH1N1
analysis period 17 April to 30 May were 0.48 (0.18–1.30) and 0.73
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PLoS Medicine | www.plosmedicine.org 4 April 2010 | Volume 7 | Issue 4 | e1000258(0.25–2.16), respectively, and for the age stratum ,50 years were
0.55 (0.16–1.93) and 0.87 (0.23–3.32), respectively. Crude and
adjusted ORs for TIV effect on seasonal influenza were also ,1f o r
the full pH1N1 analysis period spanning 17 April to 22 July.
Quebec Population Case-Control Study
Among community members who answered the telephone survey
as potential controls, the participation rate before applying exclusions
was 62% (630/1,014) for the Quebec case-control study (details
provided in Text S4, Appendix D1). After exclusion criteria were
applied, 384 community cases, 270 hospitalized cases, and 603
community controls were available for the Quebec case-control
analysis (Text S4, Appendix D1). Participant profiles are shown in
T a b l e4a n di nm o r ed e t a i li nT e x tS 4 ,A p p e n d i xD 2 .I nc o m m u n i t y
controls aged 12–19, 20–34, 35–44, and 45–64 years, TIV coverage
for the 2008–09 season were 6% (8/125), 16% (16/101), 18% (13/
Table 2. Sentinel test-negative case-control study: Participant profile by analysis period (seasonal influenza and pH1N1).
Participant Attribute Category Subcategory
Seasonal Influenza Analysis Period
(ILI Onset: 1 November 2008 to 31
March 2009)
pH1N1 Analysis Period (ILI Onset: 17
April 2009 to 22 July 2009)
Cases
(N=672),
n/N (%)
Controls
(N=857),
n/N (%)
ALL
(N=1,529),
n/N(%)
Cases
(N=144),
n/N (%)
Controls
(N=536),
n/N (%)
ALL
(N=680),
n/N(%)
2008–09 TIV Receipt 97 (14) 287 (33) 384 (25) 45 (31) 166 (31) 211 (31)
Age (y) 1–8 100 (15) 93 (11) 193 (13) 13 (9) 41 (8) 54 (8)
9–19 176 (26) 123 (14) 299 (20) 59 (41) 66 (12) 125 (18)
20–49 311 (46) 384 (45) 695 (45) 59 (41) 272 (51) 331 (49)
50–64 69 (10) 172 (20) 241 (16) 10 (7) 109 (20) 119 (18)
$65 16 (2) 85 (10) 101 (7) 3 (2) 48 (9) 51 (8)
Median (range), y 23 (1–85) 38 (1–92) 30 (1–92) 20 (2–68) 38 (1–92) 33 (1–92)
2008–09 TIV immunized by age group 1–8 14 (14) 20 (22) 34 (18) 5 (38) 4 (10) 9 (17)
9–19 14 (8) 23 (19) 37 (12) 13 (22) 6 (9) 19 (15)
20–49 39 (12) 86 (22) 125 (18) 22 (37) 63 (23) 85 (26)
50–64 17 (25) 84 (49) 101 (42) 2 (20) 60 (55) 62 (52)
$65 13 (81) 74 (87) 87 (86) 3 (100) 33 (69) 36 (71)
Sex Female 371 (55) 503 (59) 874 (57) 79 (55) 332 (62) 411 (60)
Interval between ILI onset and specimen
collection
#4 d 569 (85) 651 (76) 1220 (80) 128 (89) 418 (78) 546 (80)
5–7 d 103 (15) 206 (24) 309 (20) 16 (11) 118 (22) 134 (20)
Median (range) 3 (0–7) 3 (0–7) 3 (0–7) 2 (0–7) 3 (0–7) 3 (0–7)
With chronic conditions N 89 (13) 199 (23) 288 (19) 23 (16) 102 (19) 125 (18)
Vaccinated 2008–09 37 (42) 133 (67) 170 (59) 14 (61) 61 (60) 75 (60)
Without chronic conditions N 583 (87) 658 (77) 1241 (81) 121 (84) 434 (81) 555 (82)
Vaccinated 2008–09 60 (10) 154 (23) 214 (17) 31 (26) 105 (24) 136 (24)
Province Alberta 146 (22) 375 (44) 521 (34) 27 (19) 167 (31) 194 (29)
BC 191 (28) 189 (22) 380 (25) 19 (13) 166 (31) 185 (27)
Ontario 126 (19) 166 (19) 292 (19) 34 (24) 102 (19) 136 (20)
Quebec 209 (31) 127 (15) 336 (22) 64 (44) 101 (19) 165 (24)
Chronic condition by province Alberta 19 (13) 99 (26) 118 (23) 6 (22) 34 (20) 39 (20)
BC 27 (14) 40 (21) 67 (18) 6 (32) 39 (23) 45 (24)
Ontario 20 (16) 33 (20) 53 (18) 4 (12) 10 (10) 14 (10)
Quebec 23 (11) 27 (21) 50 (15) 7 (11) 19 (19) 26 (16)
2008–09 TIV immunized by province Alberta 15 (10) 113 (30) 128 (25) 9 (33) 56 (34) 65 (34)
BC 20 (10) 55 (29) 75 (20) 4 (21) 46 (28) 50 (27)
Ontario 32 (25) 75 (45) 107 (37) 11 (32) 37 (36) 48 (35)
Quebec 30 (14) 44 (35) 74 (22) 21 (33) 27 (27) 48 (29)
2007–08 TIV immunized by province
a Alberta 28 (20) 121 (33) 149 (29) 8 (30) 52 (33) 52 (28)
Ontario 47 (39) 80 (51) 127 (46) 14 (48) 41 (41) 41 (32)
Quebec 33 (16) 40 (33) 73 (22) 18 (31) 28 (29) 28 (18)
aBC did not collect information on 2007–08 vaccine status. 2007–08 percentages derived based on participants for whom vaccine status known. Denominators do not
include those with missing information (never exceeding four missing counts for any age category).
doi:10.1371/journal.pmed.1000258.t002
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CCHS for Quebec as measured for the 2007–08 season (Text S3,
Appendix C) [16]. The proportion of controls with underlying
medical conditions eligible for TIV was also comparable to
population estimates by age (Text S4, Appendix D2) [15].
The crude OR for a 2008–09 TIV effect on pH1N1 community
cases was significant compared to controls (2.47 [1.85–3.30])
(Table 5). Crude OR was also significant for hospitalized (3.20
[2.34–4.38]) cases (Table 5). After adjustment for age, chronic
conditions, sex, and HCW status, the OR for community cases
was 2.48 (1.80–3.42) and for hospitalized cases was 2.16 (1.47–
3.17) (Figure 1, Table 5). TIV receipt did not appear to increase
the risk when comparing hospitalized to community cases
(adjusted OR of 0.97 [0.66–1.42]).
Ontario Test-Negative Case-Control Study
Text S5, Appendix E1 outlines inclusion and exclusion criteria
resulting in 250 community cases, 136 hospitalized cases, and 288
test-negative community controls available for analysis in the Ontario
test-negative case-control study. Baseline characteristics of commu-
nity or hospitalized cases and controls are shown in Table 4 and in
more detail in Text S5, Appendix E2. Community and hospitalized
cases were younger than controls but reported similar health care–
seeking behavior as measured by the median number of physician
visits in the prior 12 months (Table 4). Among participants reporting
any ‘‘flu-like’’ symptoms at the time of influenza testing, 72% (166/
230) of community and 73% (93/130) of hospitalized cases reported
symptoms consistent with ILI, compared to 41% (106/256) of
controls (59 participants were unable to recall specific symptoms).
Among controls 20–49 years of age, 31% (38/123) had received TIV,
slightly higher (by ,5%-10%) compared to people 20–44 years from
the 2007–08 CCHS for Ontario (Text S3, Appendix C) [16]. The
proportion of controls aged 12–49 years with a chronic condition
(18/143; 11%) was within the expected range based on available
population estimates [15].
After adjustment for age, chronic conditions, sex, and HCW
status, the OR for TIV effect on pH1N1 was 1.95 [1.27–2.99] for
community cases compared to controls (Figure 1, Table 5). For
hospitalized cases, the OR was 1.19 [0.61–2.32] (Table 5).
Adjustment for neither the number of primary care visits in the
previous 12 months (marker for health care–seeking behavior) nor
number of children in the household (marker for exposure risk)
had influence except to slightly increase ORs. Interval between
symptom onset and specimen collection was available for 141/250
(56%) of the community cases and 171/229 (60%) of the test-
negative controls. With restriction to only community cases and
controls known to be tested within 4 days of symptom onset, the
fully adjusted OR for TIV effect on pH1N1 increased to 2.37
(1.22–4.60). Restriction to only participants known to have had
ILI gave consistent results, but with reduced power owing to small
Figure 1. Summary of main findings. Fully adjusted effect measures and 95% confidence intervals from four epidemiologic studies in Canada to
assess the association between 2008–09 trivalent inactivated influenza vaccine (TIV) and risk of community-based seasonal influenza and pH1N1
illness. *Note: Boxes show point estimates for the OR for each study/subgroup except the Quebec prospective cohort study for which the effect
measure displayed is the RR. See Tables 1, 3, and 5 for covariates included in adjusted analyses. RR for the Quebec prospective cohort study was age-
stratified but not further adjusted (see tables 1 and 6). LCL, lower confidence limit; UCL, upper confidence limit.
doi:10.1371/journal.pmed.1000258.g001
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risk of hospitalization when hospitalized and community cases
were compared (adjusted OR of 0.68 [0.41–1.13]).
Household Transmission Study
Forty-seven households participated in the Quebec household
transmission study. This included 47 primary cases, six members
who were symptomatic before the primary case, and 120 other
members. Among these 120 household members (median age 29
years, range 0–61 years), 32/120 (27%) had received the 2008–09
TIV, 8/48 (17%) of children and 24/72 (33%) of adults. Timeline
to the first specimen collection after identification of the primary
case was similar between vaccinated and unvaccinated partici-
pants at a median of 3 (range 1–14) versus 3 (range 1–16) days.
The proportion of children with chronic conditions was 0% (0/8)
for the vaccinated and 15% (6/40) for the unvaccinated, whereas
for adults it was 21% (5/24) and 23% (11/48), respectively.
SARs by outcome category for vaccinated compared to unvacci-
nated children and adults are presented in Table 6. TIV was not
associated with increased risk of nonspecific respiratory symptoms
(p=0.40) for any age category. No increased risk was found in
children for any outcome category, but with only eight vaccinated
pediatric participants, no definitive conclusions should be drawn.
Among the larger sample of adults, TIV was associated with
significantly increased risk for more specific outcomes of ILI
syndrome (RR 3.20 [95% CI 1.17–8.74]) and laboratory-confirmed
pH1N1 regardless of symptoms (RR 2.18 [1.13–4.20]). Results were
essentially unchanged and remained significant with adjustment for
sex. Comparison of syndrome severity among vaccinated versus
unvaccinated laboratory-confirmed cases overall showed no signifi-
cant differences, with similar mean number of days during which the
patient was unable to carry on daily activities (2.7 versus 2.4) and
during which the patient was bedridden (1.4 versus 1.5).
Discussion
To assess the association between TIV and pH1N1 risk that was
first identified in Canada during the late spring of 2009, several
Table 3. Sentinel test-negative case-control study: ORs (95% CIs) for 2008–09 TIV effect on seasonal and pH1N1 illness overall and
stratified by age, with adjustment for relevant covariates, and with additional restrictions as specified.
Covariates Overall Age ,50 Years Age $50 Years
Seasonal
Influenza,
N=1,529
pH1N1
a,
N=680
Seasonal
Influenza,
N=1,187
pH1N1
a,
N=510
Seasonal
Influenza,
N=342
pH1N1
a,
N=170
Unadjusted 0.33 (0.26–0.43) 1.01 (0.68–1.51) 0.47 (0.34–0.65) 1.84 (1.17–2.89) 0.34 (0.20–0.57) 0.43 (0.13–1.37)
Chronic conditions (yes/no) 0.37 (0.28–0.48) 1.07 (0.71–1.62) 0.47 (0.34–0.66) 1.85 (1.16–2.96) 0.37 (0.22–0.64) 0.40 (0.12–1.31)
Age
b 0.46 (0.35–0.60) 1.87 (1.19–2.94) 0.48 (0.35–0.67) 2.39 (1.47–3.89) 0.38 (0.22–0.67) 0.44 (0.14–1.45)
Province (BC, AB, ON, QC) 0.32 (0.24–0.42) 1.01 (0.67–1.53) 0.47 (0.34–0.66) 1.85 (1.15–2.97) 0.30 (0.17–0.52) 0.43 (0.13–1.42)
Interval since ILI onset (#4d / .4 d) 0.34 (0.26–0.44) 1.07 (0.72–1.60) 0.47 (0.34–0.65) 1.91 (1.21–3.00) 0.34 (0.20–0.57) 0.42 (0.13–1.37)
Age + chronic conditions 0.46 (0.35–0.62) 1.75 (1.10–2.79) 0.48 (0.34–0.67) 2.27 (1.37–3.76) 0.40 (0.23–0.71) 0.42 (0.13–1.39)
Age+chronic conditions+province 0.44 (0.33–0.60) 1.62 (1.00–2.63) 0.47 (0.33–0.66) 2.16 (1.28–3.65) 0.34 (0.19–0.62) 0.41 (0.12–1.41)
Age+chronic conditions+province+
interval
0.44 (0.33–0.59) 1.68 (1.03–2.74) 0.47 (0.33–0.66) 2.23 (1.31–3.79) 0.33 (0.18–0.61) 0.42 (0.12–1.46)
Adjusted estimates by specification
Restricted to period 17 May to 22
July
b,c
NA 1.69 (0.94–3.02) NA 2.45 (1.28–4.71) NA NSS
Restricted to Quebec and Ontario
only
b,c
0.48 (0.32–0.72) 2.15 (1.14–4.04) 0.49 (0.30–0.80) 3.03 (1.54–5.97) NSS NSS
Restricted to Quebec only
b,c 0.49 (0.27–0.90) 2.66 (1.15–6.18) 0.61 (0.28–1.32) 4.50 (1.74–11.69) NSS NSS
Restricted to Ontario only
b,c 0.48 (0.27–0.83) 1.67 (0.65–4.31)
{ 0.47 (0.24–0.90) 2.04 (0.73–5.70) NSS NSS
Restricted to adults 20–49 y only
b,c NA NA 0.43 (0.28–0.68) 2.20 (1.16–4.18) NA NA
Restricted only to those with no
chronic conditions
b,c
0.43 (0.30–0.61) 1.48 (0.87–2.50) 0.42 (0.29–0.61) 2.39 (1.34–4.29) NSS NSS
Vaccine status definition
Immunized in 2007–08
b,c,d (62008–09) 0.72 (0.52–0.99) 1.58 (0.93–2.71) 0.79 (0.54–1.14) 1.89 (1.06–3.38) NSS NSS
Immunized in 2007–08 but not 2008–
09
b,c,d
1.00 (0.63–1.60) 1.48 (0.63–3.44) 1.00 (0.60–1.66) 1.33 (0.54–3.23) NSS NSS
Immunized in 2008–09 but not 2007–
08
b,c,d
0.23 (0.10–0.52) 1.91 (0.72–5.05) 0.17 (0.06–0.47) 2.06 (0.70–6.02) NSS NSS
Immunized in 2007–08 and 2008–09
b,c,d0.47 (0.32–0.69) 1.65 (0.92–2.95) 0.54 (0.34–0.86) 2.18 (1.15–4.14) NSS NSS
aSpecimens positive for seasonal influenza (29) or of unknown subtype (2) were excluded as controls from pH1N1 analysis period.
bAdjusted for age as 1–8, 9–19, 20–49, 50–64, and $65 y, where possible, and 1–8, 9–49, $50 y where zero cells preclude adjustment with finer age categories
(indicated by {); not further age adjusted for 20–49 years. Referent age category was the last age group included in each analysis, e.g., for overall analyses it was the
category $65 y, and for the analysis restricted to those ,50 y, it was the category 20–49 y.
cFully adjusted includes chronic conditions (yes/no), age, province (as appropriate), and interval since ILI onset (#4d / .4d ) ;
dIncludes data only from Alberta, Ontario and Quebec; BC did not collect information on 2007–08 immunization status. Children ,3 y excluded from these analyses.
NA, not applicable; NSS, insufficient sample size precluding reliable estimation.
doi:10.1371/journal.pmed.1000258.t003
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when pH1N1 continued to circulate in Canada. As reported here,
this included incident (sentinel network) and retrospective case-
controlmethodswith bothtest-negativeandconventionalcommunity
controls as well as a prospective cohort study. In this paper we report
the expected finding that 2008–09 TIV was associated with a
significant (56%) reduction in the risk of medically attended illness
due to seasonal influenza. However, we also report the unexpected
finding that TIV receipt was subsequently associated with a
statistically significant (1.4- to 2.5-fold) increased risk of medically
attended illness due to the novel pH1N1 virus (Figure 1). Because the
latter result is contrary to established knowledge, greater scrutiny is
required to determine whether these associations are more likely on
balance to be real (causal) or due to a methodological flaw (bias).
Reliance on observational methods means that even careful study
design, implementation, and analysis cannot rule out the possibility of
random variation (chance) or bias (selection, information) or
confounding in explaining results. Consistency of results across
different designs in various populations and with substantial sample
sizes provides some reassurance against random variation, but the
possible contributions of bias or confounding still warrant careful
consideration.
Table 4. Quebec and Ontario pH1N1 case-control studies: Participant profiles.
Participant Attribute Subcategory QUEBEC STUDY ONTARIO STUDY
Community
Cases, n (%)
Hospitalized
Cases, n (%)
Community
Controls, n
(%)
Community
Cases, n (%)
Hospitalized
Cases, n (%)
pH1N1-
negative
controls,
n( % )
N 384 270 603 250 136 295
Age 6–59 mo 12 (3) 35 (13) 40 (7) 17 (7) 20 (15) 27 (9)
5–19 y 158 (41) 73 (27) 201 (33) 134 (54) 57 (42) 72 (24)
20–34 y 89 (23) 40 (15) 101 (17) 30 (12) 26 (19) 58 (20)
35–49 y 62 (16) 50 (18) 114 (19) 36 (14) 17 (13) 67 (23)
50–59 y 44 (11) 37 (14) 88 (15) 24 (10) 8 (6) 41 (14)
$60 y 19 (5) 35 (13) 59 (10) 9 (4) 8 (6) 30 (10)
Median (range) 23 (1–84) y 28 (1–95) y 29 (1–96) y 15 (1–77) y 16 y (8 mo to 85 y) 32 (1–85) y
Symptoms Fever+cough 270 (70) 218 (59) 18 (3) 167 (67) 97 (71) 109 (41)
ILI 261 (68) 159 (59) 15 (2) 166 (66) 93 (68) 107 (40)
Female 217 (56) 144 (53) 353 (59) 155 (62) 94 (69) 188 (65)
Comorbidity
a 96 (25) 164 (61) 95 (16) 35 (14) 51 (38) 51 (18)
Smoker
b,c 43 (11) 47 (17) 85 (14) 21 (18) 20 (30) 61 (21)
HCW
d 68 (18) 8 (3) 37 (6) 17 (7) 8 (6) 23 (8)
Median physician visits prior year N/A N/A N/A 3 4 3
Median number of children in
household
N/A N/A N/A 1 1 0
TIV status 2008–09 145 (38) 119 (44) 119 (20) 109 (44) 46 (34) 105 (36)
2007–08
c 151 (40) 120 (47) 132 (22) 124 (50) 64 (47) 119 (41)
2007–08
c only 29 (8) 19 (7) 34 (6) 28 (11) 22 (16) 35 (19)
2008–09 only 23 (6) 18 (7) 20 (3) 13 (5) 4 (3) 19 (11)
2007 and 2008
c 122 (32) 99 (39) 98 (16) 96 (38) 42 (31) 84 (29)
5i n5y
c 80 (22) 74 (32) 71 (13) 69 (30) 34 (30) 60 (20)
$1 in 5 y 198 (52) 154 (57) 182 (30) 164 (66) 88 (65) 171 (58)
None in 5 y 182 (47) 94 (35) 421 (70) 76 (33) 35 (30) 124 (42)
1–3 in 5 y
c 88 (24) 38 (17) 75 (14) 68 (29) 34 (30) 93 (32)
4–5 in 5 y
c 101 (27) 83 (36) 85 (15) 89 (38) 46 (40) 78 (26)
No comorbidity (N) 288 106 508 207 83 231
TIV 2008–09 99 (34) 27 (25) 83 (16) 90 (43) 23 (28) 75 (32)
With comorbidity (N) 96 164 95 35 51 51
TIV 2008–09 46 (48) 92 (56) 36 (38) 16 (46) 23 (45) 24 (47)
NOTE: Where percentages do not sum 100%, this is due to missing data. ILI is defined as fever+cough+one or more of: sore throat, myalgia, arthralgia, headache, or
prostration.
aComorbidity or chronic condition is defined as a vaccine-eligible underlying condition.
bSmoker is defined as any current smoking.
cFor these variables, denominators are slightly different because of missing or not applicable values.
dHCW is defined as any person working in the health care system with or without direct contact with patients.
N/A, not available.
doi:10.1371/journal.pmed.1000258.t004
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assessing these findings. The sentinel test-negative approach
provides estimates of TIV association with both seasonal and
pH1N1 risk and offers several methodological advantages. The
well-established and rehearsed sentinel system in Canada has
consistently shown TIV protection against seasonal strains over
the several years of its application, higher with better vaccine
matches and lower with relative antigenic mismatches [10–12].
Canada’s sentinel system has not previously found an increased
risk of illness associated with TIV, even at the component-specific
level in the context of substantial vaccine mismatch to circulating
seasonal strains. With the emergence of the novel pH1N1 virus in
mid-April we were able to extend routine 2008–09 sentinel
monitoring activities into the spring and summer without changes
in protocol. Canada has a publicly funded health care system that
is free to patients at use, thus removing restrictions on access that
may apply elsewhere. Sentinel physicians were specifically notified
that they were exempt from limitations on respiratory specimen
testing applied to other ambulatory care clinicians. Although
patients may have themselves altered their usual patterns of
physician visits, in accordance with protocol only submissions
meeting the ILI definition were included in sentinel analyses,
Table 5. Quebec and Ontario case-control studies: ORs (95% CI) for TIV effect on pH1N1.
OR for Previous 2008–09 TIV QUEBEC STUDY ONTARIO STUDY
Community
Cases Versus
Community
Controls,
N=384/603
Hospitalized
Cases Versus
Community
Controls,
N=270/603
Hospitalized
Cases Versus
Community
Cases,
N=270/384
Community
Cases Versus
Test-Negative
Community
Controls,
N=250/288
Hospitalized
Cases Versus
Test-Negative
Community
Controls,
N=136/288
Hospitalized
Cases Versus
Community
Cases,
N=136/250
Crude 2.47 (1.85–3.30) 3.20 (2.34–4.38) 1.30 (0.94–1.78) 1.56 (1.07–2.27) 1.03 (0.58–1.82) 0.67 (0.42–1.06)
Adjusted for:
Age (ref: 20–34 y) 3.05 (2.24–4.14) 3.22 (2.31–4.50) 1.06 (0.76–1.50) 1.93 (1.28–2.90) 1.37 (0.74–2.54) 0.68 (0.42–1.09)
Comorbidity (chronic condition) 2.32 (1.73–3.10) 1.90 (1.33–2.72) 0.94 (0.66–1.33) 1.68 (1.14–2.46) 0.94 (0.52–1.71) 0.62 (0.38–1.00)
Sex (ref: male) 2.51 (1.88–3.35) 3.31 (2.41–4.54) 1.32 (0.96–1.82) 1.55 (1.07–2.26) 1.03 (0.58–1.82) 0.67 (0.42–1.05)
HCW 2.16 (1.61–2.91) 3.31 (2.41–4.54) 1.60 (1.14–2.22) 1.62 (1.10–2.37) 1.09 (0.61–1.95) 0.67 (0.43–1.07)
Physician visits
a 1.60 (1.08–2.37) 1.03 (0.56–1.88) 0.65 (0.41–1.06)
Age+comorbidity 2.86 (2.10–3.90) 2.07 (1.42–3.03) 0.80 (0.55–1.16) 2.06 (1.35–3.13) 1.21 (0.63–2.30) 0.67 (0.41–1.11)
Age+comorbidity+sex 2.90 (2.12–3.96) 2.12 (1.45–3.10) 0.82 (0.56–1.18) 2.04 (1.34–3.12) 1.23 (0.64–2.36) 0.67 (0.40–1.10)
Age+comorbidity+sex+HCW 2.48 (1.80–3.42) 2.16 (1.47–3.17) 0.97 (0.66–1.42) 1.95 (1.27–2.99) 1.19 (0.61–2.32) 0.68 (0.41–1.13)
Age+comorbidity+sex+physician visits N/A N/A N/A 2.08 (1.33–3.26) 1.22 (0.60–2.47) 0.67 (0.39–1.13)
Adjusted
b OR by category of seasonal influenza immunization in persons aged $5y :
Immunized in 2007–2008 2.55 (1.84–3.54) 2.19 (1.47–3.26) 1.01 (0.68–1.53) 1.98 (1.28–3.06) 3.17 (1.56–6.46) 1.20 (0.71–2.05)
Immunized in 2007–08 and 2008–09 2.55 (1.79–3.63) 2.26 (1.47–3.47) 1.01 (0.66–1.54) 2.32 (1.43–3.75) 2.09 (0.99–4.40) 0.92 (0.53–1.59)
$1 in last 5 y versus never 2.84 (2.08–3.87) 2.52 (1.70–3.73) 1.09 (0.73–1.64) 1.95 (1.26–3.03) 2.80 (1.34–5.82) 1.33 (0.76–2.33)
5 in last 5 y versus never 2.77 (1.80–4.28) 3.24 (1.97–5.34) 1.42 (0.86–2.37) 1.81 (1.09–3.02) 2.03 (0.93–4.43) 0.92 (0.52–1.65)
Adjusted
b OR by number of vaccinations in prior 5 y in persons aged $5y
0 Reference Reference Reference Reference Reference Reference
1, 2, 3 2.56 (1.75–3.74) 1.21 (0.72–2.01) 0.68 (0.41–1.13) 1.56 (0.94–2.57) 2.22 (0.98–5.02) 1.35 (0.70–2.61)
4, 5 2.92 (1.98–4.30) 2.17 (1.38–3.41) 0.90 (0.57–1.43) 2.57 (1.51–4.38) 3.80 (1.60–8.99) 1.32 (0.70–2.49)
Adjusted
c OR by strata
No comorbidity 2.71 (1.87–3.93) 1.77 (1.04–2.99) 0.68 (0.38–1.19) 2.46 (1.52–3.99) 1.77 (0.78–4.07) 0.53 (0.29–0.98)
With comorbidity
d 1.72 (0.87–3.38) 2.93 (1.61–5.36) 1.47 (0.84–2.58) 0.80 (0.28–2.26) 0.64 (0.20–2.08) 1.53 (0.53–4.44)
Age ,50 y
e 2.54 (1.76–3.65) 2.27 (1.44–3.58) 1.00 (0.64–1.51) 1.99 (1.24–3.21) 1.23 (0.59–2.57) 0.63 (0.37–1.08)
Age $50 y
d,f 2.03 (1.04–3.96) 2.06 (1.03–4.13) 1.25 (0.55–2.84) 1.89 (0.73–4.91) 1.21 (0.24–6.18) 1.29 (0.26–6.50)
Age 50–59 y
g 4.23 (1.81–9.92) 1.48 (0.58–3.76) 0.45 (0.14–1.38) N/A N/A N/A
Age 60 y+
h 0.66 (0.22–2.01) 3.32 (1.06–9.74) 5.36 (1.44–19.95) N/A N/A N/A
Ontario Study: Test date was included as a binary variable (before/after June 11, 2009) in all Ontario models (see text).
aPhysician visits=number of visits to family doctor/primary care physician in the 12 mo prior.
bAdjusted for age (5–19, 20–34 [as reference], 35–49, 50–59, and 60+ y)+comorbidity+sex+HCW.
cAdjusted for age+sex+HCW.
dIn Ontario adjustment for HCW not performed if not represented in all cells.
eAdjusted for age (,10, 10–19 y, and 20–49 [as reference])+comorbidity+sex+HCW.
fAdjusted for age (50–59 [as reference] and 60+ y)+comorbidity+sex+HCW.
gAdjusted for chronic condition+sex+HCW.
hAdjusted for comorbidity+sex.
N/A, not available.
doi:10.1371/journal.pmed.1000258.t005
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seeking or illness severity. Influenza immunization registries do not
exist in participating provinces, so all vaccine uptake estimates rely
upon patient self-reports and cannot be further confirmed.
Although imperfect recall may have introduced misclassification
of vaccine status, immunization history was recorded by the
clinician at the time of test submission, before the test result was
known, thus helping to attenuate possible differential in recall by
outcome. We also excluded submissions with unknown vaccine
status. Unlike the Ontario and Quebec case-control studies, the
sentinel approach did not collect information on occupation.
Adjustment for HCW status, however, did not meaningfully
influence ORs in the Ontario test-negative or Quebec population
case-control studies, and when they were excluded in the Quebec
test-negative approach, ORs were unchanged or slightly increased.
To further address the possible influence of health care–seeking
behavior, we adjusted for the timeliness of medical visits in the
sentinel and Ontario case-control studies and for chronic conditions
in all studies. Comorbidity was analyzed as a dichotomous variable.
Although all chronic conditions may not exert the same influence,
further stratification on select categories of chronic conditions did not
influence ORs in subanalyses (not shown; available upon request). It
is possible that misclassification of comorbidity may have biased our
results. If this effect exists in the sentinel study, however, it should be
minor; underlying conditions were also recorded before test results
were known, and our findings mainlyreflectthe experience of healthy
young adults and school-aged children. It is important to note that
subanalyses within the stratum of participants without any chronic
conditions showed a consistent vaccine effect. The lower ORs and
apparent absence of TIV effect on pH1N1 risk in the older stratum of
sentinel study participants are noteworthy. During both analysis
periods, the proportion of controls $50 years of age, and especially
$65 years of age, who reported chronic conditions and who received
TIV were higher than expected based on community surveys,
flagging a possible concern with the controls in that stratum. Given
the small sample size and the expected variation in important
characteristics such as pre-existing pH1N1 immunity across advan-
cing years of life, no specific conclusions can be drawn for older
individuals based on these data [17,18].
A strength of the sentinel study is that it enabled a direct
comparison of participant profiles and vaccine effect using the
same methods for seasonal and pH1N1 analysis periods. With
similar methods and participant profiles for the two analysis
periods, we found very different TIV associations with influenza
risk, notably among younger persons. We found significant TIV
protection against seasonal influenza and a protective trend
against seasonal strains that persisted during the pH1N1 analysis
period. ORs,1 for seasonal influenza that persisted after April 17
make it more difficult to attribute the ORs.1 for pH1N1 using
the same methods during the same period to newly introduced
bias.
With its randomly selected community controls, the Quebec
population case-control study likely provides the upper bound of a
risk estimate for pH1N1 associated with TIV, since standardiza-
tion of health care–seeking behavior between cases and controls
was not afforded. Results from this design may be affected by
differential characteristics among those who sought care or testing
compared to community controls. The initial Quebec experience
with the test-negative case-control design also provides an
important caution regarding the potential for selection bias with
this approach. This caution applies especially to test-negative
designs when specimens are drawn from general laboratory
submissions and/or when limitations are placed on testing, such as
to individuals with chronic conditions or severe illness (see Text
S2, Appendix B1a). Careful assessment of participant profiles
showed that the test-negative controls in the initial Quebec study
were not adequately representative of the source population from
which the cases arose, although with appropriate adjustment for
relevant covariates and restriction to patients with similar clinical
presentation, the same increased risk of pH1N1 illness in
association with 2008–09 TIV was found (Text S2, Appendix
B1a–B1e).
Ontario applied a later restriction on laboratory testing
compared to Quebec (11 June versus 15 May), and the Ontario
dataset showed test-negative controls to be representative of the
case source population. Both cases and controls sought care and
had similar health care–seeking behavior, as evidenced by the rate
of physician visits in the previous 12 months and by the proportion
with chronic conditions. Immunization rates among test-negative
controls may have slightly exceeded population estimates for
Ontario in young adults (tending to decrease the OR) but a
statistically significant effect was still observed. Adjustment for
other relevant covariates generally increased ORs among
vaccinated participants. Sample sizes in Ontario were smaller
Table 6. Quebec household transmission study: Secondary pH1N1 attack rates among household members by 2008–09 TIV status.
Outcome Category
and 2008–09 TIV Status
Children
,18 y, N=48
RR (95% CI)
Vaccinated Versus
Unvaccinated
Children
Adults $18 y,
N=72
RR (95% CI)
Vaccinated Versus
Unvaccinated
Adults Total, N=120
RR (95% CI)
Vaccinated Versus
Unvaccinated Overall
Respiratory symptoms
Received TIV 4/8 (50%) 0.71 (0.35–1.47) 13/24 (54%) 0.96 (0.62–1.50) 17/32 (53%) 0.85 (0.59–1.22)
Did not receive TIV 28/40 (70%) 1 27/48 (56%) 1 55/88 (63%) 1
Influenza-like illness (ILI) syndrome
Received TIV 3/8 (38%) 1.00 (0.38–2.66) 8/24 (33%) 3.20 (1.17–8.74) 11/32 (34%) 1.51 (0.82–2.80)
Did not receive TIV 15/40 (38%) 1 5/48 (10%) 1 20/88 (23%) 1
Any PCR-confirmed pH1N1
Received TIV 2/8 (25%) 0.59 (0.17–2.06) 12/24 (50%) 2.18 (1.13–4.20) 14/32 (44%) 1.38 (0.84–2.26)
Did not receive TIV 17/40 (43%) 1 11/48 (23%) 1 28/88 (32%) 1
ILI is defined as fever + cough + one or more of sore throat, myalgia, arthralgia, headache, or prostration.
doi:10.1371/journal.pmed.1000258.t006
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intervals surrounding ORs were wide, particularly among
stratified analyses. Point estimates, however, remained consistent
with other studies. A comparison between hospitalized and
community cases in both the Quebec and the Ontario designs
suggests that once pH1N1 illness was acquired, the risk of pH1N1
hospitalization was not further increased among TIV recipients.
An increase in the absolute number of hospitalizations, however,
would nevertheless still occur with this association, since that
number is determined by the risk of becoming ill (increased)
multiplied by the risk of hospitalization once ill (unchanged).
Finally, with its active and prospective follow-up of all household
members, the Quebec household transmission study provided
corroborating evidence that was able to avert the potential for
health care–seeking and other selection biases known to affect
case-control studies. The results were consistent with other
findings, and statistical significance was observed. A limitation of
that study, however, is the small sample size that precluded further
stratification.
Confounding by indication may spuriously lower VE estimates
in observational studies because influenza vaccine is administered
to people at greater risk of clinical illness and more likely to seek
care (such as those with chronic conditions) [19]. More recent
publications have also reported overestimation of influenza
vaccine protection against serious outcomes among elderly persons
as a result of better general health status among vaccinated
compared to unvaccinated people (healthy user bias) [20,21].
Influences on immunization status can thus skew estimates in
either direction. It may be that in young people chronic conditions
exert a greater influence in decreasing VE estimates (increasing
ORs) than the counterforce of healthy user bias. Our national
sentinel study population, however, included few participants with
chronic conditions, and to further address this possible influence
we applied recognized analysis techniques of restriction, stratifica-
tion, and adjustment to all studies. We cannot rule out that these
efforts were incomplete and that an unmeasured bias or residual
confounding remains.
Several studies from Australia [22], Mexico [23,24], and the US
[25,26] have instead reported null or protective effects of 2008–09
TIV against pH1N1 illness based on test-negative case-control
[22–25], case-cohort [25], or ILI outbreak investigations [26].
One other test-negative case-control analysis from a US outbreak
found a statistically significant increased risk, with an unadjusted
OR of 2.9 (95% CI 1.8–4.69) for pH1N1 illness among military
beneficiaries who received influenza vaccine within the previous
12 months [27]. Unlike in Canada, however, this association was
driven primarily by receipt of live attenuated vaccine. Discrepant
results across studies may reflect either differences in methods or
real variation in the effect of specific vaccines, immunization
programs, or population immunity. Most of the studies published
to date, however, have not presented sufficient participant
characteristics to properly assess methodological issues, sources
of bias or confounding, or the validity of results. As previously
highlighted, the importance of the public health and scientific
implications requires that analyses of TIV effect on pH1N1 risk be
more rigorous [28,29]. At a minimum, a detailed profile of cases
and controls specifically included in vaccine effectiveness analyses
should be displayed by vaccine status, age, and chronic conditions,
as well as timeliness of specimen collection and other recognized
influences. Where participant characteristics have been presented
by investigators, conspicuous evidence of selection bias can be seen
to explain opposite findings of TIV protection against pH1N1
[23,28]. In the detailed participant profiles we display for each of
the four studies we report, evidence for this type of bias is not
obvious, but that does not rule it out. We also cannot rule out the
possibility that the increased risk of pH1N1 found in Canada was
an effect specific to the Canadian vaccine: it is noteworthy that
ORs were highest in Quebec, where a greater proportion of
domestically produced vaccine is distributed than in the rest of
Canada. However, even if our findings are considered a
‘‘Canadian problem,’’ if causal in nature they would still have
wider implications for our understanding of influenza immuno-
pathogenesis.
In the event that our findings are valid and reflect a causal
association by which prior receipt of TIV increased the risk of
PCR-positive pH1N1 illness, several biological mechanisms have
been considered to explain them. These proposed mechanisms
must each be viewed as speculative since our epidemiologic studies
were not designed to assess them. One hypothesis is that repeat
immunization effectively blocks the more robust, complex, and
cross-protective immunity afforded by prior infection. This
mechanism was suggested by Hoskins et al. in the mid-1970s in
evaluating the risk of A/H3N2 drift variants among previously
infected versus immunized boys during successive boarding school
outbreaks, with the consideration of other factors (such as viral
neuraminidase [NA]) in addition to HA antibody [30]. Bodewes et
al. have more recently shown in mice that effective vaccination
against human influenza A/H3N2 virus prevents virus-induced
(cell-mediated) heterosubtypic immunity against severe (lethal)
infection with avian influenza of a different subtype (A/H5N1)
[31,32]. That one influenza subtype may influence the risk of
infection by another is also suggested by the subtype replacement
that followed the pandemics of 1918, 1957, and 1968, although
the mechanism for that is unknown [33]. A BLAST sequence
analysis demonstrates that pH1N1 and human influenza strains
(A/H1N1 and A/H3N2, recent [since 2000] and historical [since
1974]) are nearly identical (95%–98%) with respect to their
polymerase proteins, at both the overall and the antigenic levels,
and other internal components, including M1 (94%–97%) and NP
(85%–92%) are also well-conserved (Text S6, Appendix F).
Conversely, both the HA and the NA surface proteins of recently
circulating seasonal H1N1 influenza viruses and pH1N1 are more
divergent, particularly with respect to their antigenic regions (Text
S6, Appendix F). With a greater likelihood of seasonal influenza
infection, unvaccinated people may have had a greater opportu-
nity to develop cross-protective cell-mediated immunity to the
more conserved internal viral components of pH1N1. Since those
immunized in a given season may have been repeatedly
immunized over several seasons, they may have lost multiple
opportunities for infection-induced cross-immunity. TIV recipi-
ents may have boosted antibody to HA/NA (the only TIV
components), effectively protecting against seasonal influenza, but
without a cross-protective effect against the markedly different
surface antigens of pH1N1.
If this hypothesis explains our results, it also reassuringly implies
that the TIV effect we have observed on pH1N1 risk would be
induced again only if seasonal influenza circulates before pH1N1
and TIV blocks the potential cross-protection of that heterologous
infection. There are, however, at least two considerations that
oppose this hypothesis. First, the risk of laboratory-confirmed
influenza illness per se—the outcome reported by our studies—is
believed to be determined primarily by protective antibodies to
viral surface proteins. As indicated above, the antigenic distance
between the HA and NA surface proteins of pH1N1 and recently
circulating human H1N1 strains is large, making cross-protection
on that basis less likely. Differences in severe outcomes may be
explained by cross-protective cell-mediated immunity, as shown by
Bodewes et al. to be induced by prior infection with heterologous
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vaccine status and that is not what we are trying to explain. The
role of cell-mediated or other immune correlates of cross-
protection against influenza illness per se likely warrants further
study. Second, in order to show a 2-fold increase in pH1N1 illness,
this hypothesis would require implausible assumptions of un-
reasonably high prior seasonal influenza attack rates, cross-
protection against pH1N1 illness, and/or the effective block of
that cross-protection by TIV (see Text S7 Appendix G).
We have also considered the possibility of a direct immune
mechanism to explain our results. One such mechanism is based
on the induction of low-affinity/non-neutralizing but cross-
reactive antibodies by TIV to the major surface proteins. Such
antibodies are typically identified within an ‘‘original antigenic
sin’’ response [34–36], the relevance of which has long been
debated for influenza, but for which Kim and colleagues have
recently provided evidence in the mouse model [37]. In a related
concept, antibody-dependent enhancement (ADE) of virus repli-
cation may occur when preexisting low levels of weakly heterotypic
antibodies (cross-reactive but not cross-protective) bind to virus but
instead of neutralizing the virus, form bridging complexes that
facilitate enhanced uptake and increased virus production by the
target cell [38–40]. Original antigenic sin and ADE of virus
replication have been described for secondary heterotypic dengue
infections, but also in vitro for other viruses such as respiratory
syncytial virus, Ebola, HIV, etc. [38–40]. ADE has also been
shown in vitro for influenza uptake by macrophages, although
these are not generally considered the main target cell for
influenza replication [41–44]. Interestingly, vaccine-potentiated
pneumonia has been reported following heterologous swine
influenza challenge in pigs, and enhanced pneumonia due to
heterologous swine influenza has also been reported in piglets
vaccinated in the presence of maternal antibody, with ADE
invoked by authors to possibly explain these findings [45,46]. In
further support of a direct vaccine-induced effect to explain our
findings, a recent pH1N1 challenge study of influenza-naı ¨ve ferrets
has shown that, compared to a nonimmunized control group,
prior receipt of 2008–09 seasonal vaccine (notably live attenuated
vaccine) was associated with slight worsening of day 3 upper
airway viral loads, clinical disease, and mortality, with ADE also
invoked by authors as a possible explanation [47]. We did not find
increased pH1N1 severity associated with seasonal vaccine in our
epidemiologic studies; this observation may reflect intrinsically less
virulent virus or, as described above, other intact viral clearance
mechanisms [48].
In considering the ADE hypothesis, it should be recognized that
this proposed mechanism has not been previously linked to
epidemiologic observations for influenza in humans. ADE may
require a precise balance of antigenic distance and cross-reactive
versus neutralizing antibody to be manifest. The 2009 pandemic
differs from other influenza epidemics or pandemics in that it has
been caused by a novel virus distantly related to but nevertheless
within the same HA/NA subtype as recently circulating H1N1
viruses.The roleofantibodyconcentrations in ADE is under debate,
so it is difficult to know whether our findings during spring–summer
2009 in Canada, if explained in this way, would have been observed
duringfall–winter2009–10with(orwithout)repeatadministrationof
TIV, or whether seasonal vaccines may differ in the relative
proportion of cross-reactive versus cross-protective antibody induced
to pH1N1. In the end, our results may seem counterintuitive, but
they cannot be dismissed on the basis that no biological mechanism
can plausibly explain them. The mechanism may be a combination
of the above or an as-yet unknown pathway. Further empiric
evidence would be necessary to support a specific mechanism.
After the substantial autumn 2009 wave of pH1N1 and the mass
pH1N1 vaccination campaign, seasonal influenza viruses remain a
possible threat to consider for the rest of the 2009–10 winter. The
complex benefit–risk analysis for receipt of 2009–10 TIV will
ultimately depend upon the extent to which seasonal A/H1N1, A/
H3N2, or B viruses contribute to TIV-preventable morbidity this
season. It remains uncertain whether the influenza A subtype
replacement observed with previous pandemics will also occur with
this pandemic. Thus far (to 1 March2010),seasonal strains havenot
comprised a substantial proportion of influenza detections in the
northern hemisphere’s 2009–10 season, with the exception of a
recent increase in influenza B in China [49]. For the next season,
WHO has recommended that pH1N1 be included in seasonal
vaccine formulations, thereby providing direct pH1N1 protection
and obviating the possible risk we identified in association with the
seasonal vaccine in 2009 [50,51]. The possible scientific implica-
tions of our findings, however, will remain important to consider
over the long term. These include questions about influenza
immunopathogenesis, the interaction between seasonal and novel
pandemic strains, the complex immunoepidemiologic aspects of
influenza prevention and control, and how best to assess these issues
experimentally and epidemiologically.
In summary, we report findings from four epidemiologic studies
in Canada showing that prior receipt of 2008–09 TIV was
associated with increased risk of medically attended pH1N1 illness
during the spring–summer 2009. Bias cannot be ruled out in
observational studies, and therefore these findings cannot be
considered conclusive. If these observations do reflect a real
biological effect, however, they raise important questions that
warrant further scientific investigation.
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Background. Every winter, millions of people catch
influenza—a viral infection of the airways—and hundreds
of thousands of people die as a result. These seasonal
epidemics occur because small but frequent changes in the
influenza virus mean that an immune response produced
one year through infection or vaccination provides only
partial protection against influenza the next year. Annual
vaccination with killed influenza viruses of the major
circulating strains can greatly reduce a person’s risk of
catching influenza. Consequently, many countries run
seasonal influenza vaccination programs. In most of
Canada, vaccination with a mixture of three inactivated
viruses (a trivalent inactivated vaccine or TIV) is provided free
to children aged 6–23 months, to elderly people, to people
with long-term conditions that increase their risk of
influenza-related complications, and those who provide
care for them; in Ontario, free vaccination is offered to
everyone older than 6 months.
In addition, influenza viruses occasionally emerge that are
very different and to which human populations have virtually
no immunity. These viruses can start global epidemics
(pandemics) that can kill millions of people. Experts have
been warning for some time that an influenza pandemic is
long overdue and, in March 2009, the first cases of influenza
caused by a new virus called pandemic A/H1N1 2009
(pH1N1; swine flu) occurred in Mexico. The virus spread
rapidly and on 11 June 2009, the World Health Organization
declared that a global pandemic of pH1N1 influenza was
underway. By the end of February 2010, more than 16,000
people around the world had died from pH1N1.
Why Was This Study Done? During an investigation of a
school outbreak of pH1N1 in the late spring 2009 in Canada,
investigators noted that people with illness characterized by
fever and coughing had been vaccinated against seasonal
influenza more often than individuals without such illness.
To assess whether this association between prior vaccination
with seasonal 2008–09 TIV and subsequent pH1N1 illness
was evident in other settings, researchers in Canada
therefore conducted additional studies using different
methods. In this paper, the researchers report the results
of four additional studies conducted in Canada during the
summer of 2009 to assess this possible association.
What Did the Researchers Do and Find? The researchers
conducted four epidemiologic studies. Epidemiology is the
study of the causes, distribution, and control of diseases in
populations.
Three of the four studies were case-control studies in which
the researchers assessed the frequency of prior vaccination
with the 2008–09 TIV in people with pH1N1 influenza
compared to the frequency among healthy members of the
general population or among individuals who had an
influenza-like illness but no sign of infection with an
influenza virus. The researchers also did a household
transmission study in which they collected information
about vaccination with TIV among the additional cases of
influenza that were identified in 47 households in which a
case of laboratory-confirmed pH1N1 influenza had occurred.
The first of the case-control studies, which was based on
Canada’s vaccine effectiveness monitoring system, showed
that, as expected, the 2008–09 TIV provided protection
against seasonal influenza. However, estimates from all four
studies (which included about 1,200 laboratory-confirmed
pH1N1 cases and 1,500 controls) showed that prior
recipients of the 2008–09 TIV had approximately 1.4–2.5
times increased chances of developing pH1N1 illness that
needed medical attention during the spring–summer of
2009 compared to people who had not received the TIV.
Prior seasonal vaccination was not associated with an
increase in the severity of pH1N1 illness, however. That is,
it did not increase the risk of being hospitalized among those
with pH1N1 illness.
What Do These Findings Mean? Because all the
investigations in this study are ‘‘observational,’’ the people
who had been vaccinated might share another unknown
characteristic that is actually responsible for increasing their
risk of developing pH1N1 illness (‘‘confounding’’). Further-
more, the results reported in this study might have arisen by
chance, although the consistency of results across the
studies makes this unlikely. Thus, the finding of an
association between prior receipt of 2008–09 TIV and an
increased risk of pH1N1 illness is not conclusive and needs to
be investigated further, particularly since some other
observational studies conducted in other countries have
reported that seasonal vaccination had no influence or may
have been associated with reduced chances of pH1N1 illness.
If the findings in the current study are real, however, they
raise important questions about the biological interactions
between seasonal and pandemic influenza strains and
vaccines, and about the best way to prevent and control
both types of influenza in future.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1000258.
N This article is further discussed in a PLoS Medicine
Perspective by Ce ´cile Viboud and Lone Simonsen
N FightFlu.ca, a Canadian government Web site, provides
access to information on pH1N1 influenza
N The US Centers for Disease Control and Prevention
provides information about influenza for patients and
professionals, including specific information on H1N1
influenza
N Flu.gov, a US government website, provides access to
information on H1N1, avian and pandemic influenza
N The World Health Organization provides information on
seasonal influenza and has detailed information on pH1N1
influenza (in several languages)
N The UK Health Protection Agency provides information on
pandemic influenza and on pH1N1 influenza
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